

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
ImmunityBio (nogapendekin alfa	All Wales Therapeutics and Toxicology
inbakicept)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Action Bladder Cancer UK	Wales
Black Health Agency for Equality	 British National Formulary
Bladder and Bowel Community	Care Quality Commission
Bladder and Bowel UK	Department of Health, Social Services
Cancer 52	and Public Safety for Northern Ireland
Cancer Black Care	Healthcare Improvement Scotland
Fight Bladder Cancer	Medicines and Healthcare products
Independent Cancer Patients Voice	Regulatory Agency
Macmillan Cancer Support	National Association of Primary Care
Maggie's Centres	National Pharmacy Association
Marie Curie	NHS Confederation
South Asian Health Foundation	NHS Wales Joint Commissioning
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	Scottish Medicines ConsortiumWelsh Government
Healthcare professional groups	
Association of Cancer Physicians	Comparator companies
British Association of Urological	AJ Vaccines A/S (BCG)
Nurses	Hospira (docetaxel, gemcitabine)
British Association of Urological	Medac Pharma (BCG, mitomycin)
Surgeons	Seacross Pharmaceuticals (docetaxel)
British Geriatrics Society	Sun Pharma (gemcitabine)
British Institute of Radiology	Synchrony Pharma (gemcitabine)
British Oncology Pharmacy	Vygoris (mitomycin)
Association	
British Psychosocial Oncology Society	Relevant research groups
British Society of Urogenital Radiology	Cochrane Urology
British Society of Urogynaecology	Genomics England
British Uro-Oncology Group	Institute of Cancer Research
Cancer Research UK	MRC Clinical Trials Unit
Royal College of General Practitioners	National Institute for Health Research

Final stakeholder list for the evaluation of nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582] Issue date: October 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation 	Associated Public Health groups • Public Health Wales • UK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Final stakeholder list for the evaluation of nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582] Issue date: October 2025



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.